Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
CMMB reported promising OLE results for nebokitug in PSC patients. Over 90% of trial patients opted for continued participation in the study. Nebokitug showed significant safety and liver biomarker improvement in patients. Clinical events in treated patients dropped from 25.8% to 4.8% over 48 weeks. CMMB's stock rose 2.59% to $1.19 following the news.
View signal analysis